Pharmacological activities of berberine and strategies to improve its oral bioavailability
10.16438/j.0513-4870.2021-1302
- VernacularTitle:小檗碱的药理活性以及提升其口服生物利用度的策略
- Author:
Jian-xiong ZHOU
;
Song-gu WU
;
Jun-bo GONG
;
Zhen-ping WEI
- Publication Type:Research Article
- Keywords:
berberine;
pharmacological activity;
rug metabolism;
pharmacokinetics;
oral bioavailability
- From:
Acta Pharmaceutica Sinica
2022;57(5):1263-1272
- CountryChina
- Language:Chinese
-
Abstract:
Berberine is a naturally occurring benzylisoquinoline alkaloid with a wide range of pharmacological activities, such as antibacterial, anticancer, hypolipidemic, antidiabetic and antidiarrheal. Although berberine has a wide range of curative effects, the extremely low bioavailability (< 1%) limits its clinical application. Pure berberine preparations have not yet been approved for any specific disease. The low oral bioavailability of berberine is mainly due to poor solubility caused by self-aggregation under acidic conditions, low permeability, P-glycoprotein (P-gp)-mediated efflux, and liver and intestine metabolism. To improve the oral bioavailability of berberine, researchers have adopted a variety of strategies, including the application of various nano-delivery systems, penetration enhancers and P-gp inhibitors, structural modifications, and development of berberine derivatives. Improving the oral bioavailability of berberine can improve the pharmacological activity of berberine, reduce the dosage, and then reduce the toxic and side effects. This review summarized the various pharmacological activities, metabolism progress and pharmacokinetic characteristics of berberine, the newly discovered berberine target intestinal microbiota and focused on the strategies to improve the oral bioavailability of berberine by improving solubility and permeability, inhibiting P-gp efflux, and structural modification. The research on berberine was prospected, which provided guidance for the in-depth study of berberine.
